Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Recommendation of “Hold” from Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been given an average rating of “Hold” by the nine research firms that are covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $8.24.

A number of analysts recently issued reports on the company. UBS Group cut their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Guggenheim lowered their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Wells Fargo & Company dropped their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Finally, HC Wainwright decreased their price target on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th.

Insider Activity

In other Zentalis Pharmaceuticals news, Director Jan Skvarka purchased 60,000 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the acquisition, the director now directly owns 149,551 shares of the company’s stock, valued at $257,227.72. This trade represents a 67.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ingmar Bruns acquired 20,000 shares of the business’s stock in a transaction on Thursday, February 6th. The shares were bought at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the acquisition, the insider now owns 36,629 shares of the company’s stock, valued at $83,514.12. This represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Vident Advisory LLC acquired a new position in Zentalis Pharmaceuticals in the fourth quarter valued at $45,000. State of Wyoming raised its stake in Zentalis Pharmaceuticals by 124.6% during the 4th quarter. State of Wyoming now owns 34,716 shares of the company’s stock valued at $105,000 after acquiring an additional 19,262 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Zentalis Pharmaceuticals during the 4th quarter worth approximately $52,000. Nuveen Asset Management LLC grew its stake in shares of Zentalis Pharmaceuticals by 35.2% in the 4th quarter. Nuveen Asset Management LLC now owns 641,407 shares of the company’s stock valued at $1,943,000 after purchasing an additional 167,062 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Zentalis Pharmaceuticals by 8.1% in the fourth quarter. Millennium Management LLC now owns 957,563 shares of the company’s stock valued at $2,901,000 after purchasing an additional 71,477 shares during the period.

Zentalis Pharmaceuticals Stock Up 2.1 %

ZNTL stock opened at $2.48 on Wednesday. Zentalis Pharmaceuticals has a 52-week low of $1.61 and a 52-week high of $18.07. The business has a fifty day moving average of $2.60 and a two-hundred day moving average of $3.09. The stock has a market cap of $176.72 million, a price-to-earnings ratio of -1.00 and a beta of 1.81.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.